| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| Other Sizes |
| Targets |
Gefitinib impurity 5 is an impurity of gefitinib and does not have a defined pharmacological target. Gefitinib itself targets the epidermal growth factor receptor (EGFR) tyrosine kinase. The impurity is used as a reference standard for quality control.
|
|---|---|
| ln Vitro |
Gefitinib impurity 5 does not exhibit significant pharmacological activity. It is a chemical impurity of gefitinib. Its primary use is as a reference standard for the identification and quantification of impurities in gefitinib formulations by HPLC.
|
| ln Vivo |
In vivo, Gefitinib impurity 5 is not administered as a therapeutic agent. It may be present as a trace impurity in gefitinib formulations. Its safety and toxicological profile are assessed in the context of pharmaceutical quality control to ensure that impurity levels remain below acceptable limits.
|
| Enzyme Assay |
In vitro assays for Gefitinib impurity 5 typically involve its use as a reference standard in HPLC or LC-MS methods for impurity profiling of gefitinib. The compound is characterized by its retention time, UV spectrum, and mass spectrum. System suitability tests are performed to ensure proper separation from gefitinib and other impurities.
|
| Cell Assay |
For in vitro cell assays, Gefitinib impurity 5 is not typically used as a treatment. It may be tested for cytotoxicity in cell-based assays to assess its safety as an impurity. Cells are cultured and treated with the compound at various concentrations, and cell viability is assessed by standard assays. Results are used to establish acceptable impurity limits.
|
| Animal Protocol |
For in vivo animal studies, Gefitinib impurity 5 is not typically administered as a therapeutic agent. Toxicological studies may be conducted to assess the safety of this impurity at relevant exposure levels. Animals are administered gefitinib formulations containing the impurity, and toxicological endpoints are monitored.
|
| ADME/Pharmacokinetics |
Gefitinib impurity 5 (MW 319.36) has the molecular formula C₁₆H₂₁N₃O₄. It is also known as 7-methoxy-6-[3-(morpholin-4-yl)propoxy]-3,4-dihydroquinazolin-4-one. The compound is stable under recommended storage conditions.
|
| Toxicity/Toxicokinetics |
The compound is for research use only. No specific toxicity data are available. As a pharmaceutical impurity, its toxicity is assessed in the context of quality control to ensure patient safety. Standard laboratory safety precautions should be followed when handling this compound.
|
| References |
[1]. Wakeling AE, et al. ZD1839: an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 2002 Oct 15;62(20):5749-54.
|
| Additional Infomation |
Gefitinib impurity 5 (CAS# 199327-61-2) is a designated impurity of the EGFR tyrosine kinase inhibitor gefitinib. It has not been approved as a therapeutic agent. The compound is used as a reference standard in pharmaceutical quality control for impurity profiling of gefitinib formulations. It is also known as Gefitinib impurity 5.
|
| Molecular Formula |
C16H21N3O4
|
|---|---|
| Molecular Weight |
319.36
|
| Exact Mass |
319.153
|
| CAS # |
199327-61-2
|
| PubChem CID |
135399673
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
564.4±50.0 °C at 760 mmHg
|
| Flash Point |
295.2±30.1 °C
|
| Vapour Pressure |
0.0±1.5 mmHg at 25°C
|
| Index of Refraction |
1.611
|
| LogP |
0.29
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
426
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NC=NC2=C1C=C(OCCCN3CCOCC3)C(OC)=C2
|
| InChi Key |
WFUBWLXSYCFZEH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H21N3O4/c1-21-14-10-13-12(16(20)18-11-17-13)9-15(14)23-6-2-3-19-4-7-22-8-5-19/h9-11H,2-8H2,1H3,(H,17,18,20)
|
| Chemical Name |
7-methoxy-6-(3-morpholin-4-ylpropoxy)-3H-quinazolin-4-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1313 mL | 15.6563 mL | 31.3126 mL | |
| 5 mM | 0.6263 mL | 3.1313 mL | 6.2625 mL | |
| 10 mM | 0.3131 mL | 1.5656 mL | 3.1313 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
